一项关于塞来昔布对局限性前列腺癌患者影响的随机对照试验。

A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.

作者信息

Sooriakumaran Prasanna, Coley Helen M, Fox Stephen B, Macanas-Pirard Patricia, Lovell David P, Henderson Alastair, Eden Chris G, Miller Paul D, Langley Stephen E M, Laing Robert W

机构信息

Department of Urology, St. Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, Surrey, UK.

出版信息

Anticancer Res. 2009 May;29(5):1483-8.

PMID:19443354

Abstract

UNLABELLED

Cyclooxygenase-2 (COX-2) is associated with tumour promotion, inhibition of apoptosis, angiogenesis and metastasis. Celecoxib, a selective COX-2 inhibitor was investigated, in patients with clinically localized prostate cancer using immunohistochemistry.

PATIENTS AND METHODS

Patients with cT1-2 prostate cancer (n=45) were randomized to celecoxib 400mg b.d. or no treatment for four weeks prior to radical prostatectomy. Histological sections of preoperative biopsy and matched radical prostatectomy specimens were stained for markers of cell proliferation (MIB-1/Ki-67), microvessel density (CD-31 with Weidner scoring), COX-2, apoptosis (TUNEL analysis), angiogenic factors (VEGF and KDR) and HIF-1.

RESULTS

Celecoxib decreased tumour cell proliferation, microvessel density, angiogenesis and HIF-1 whilst enhancing apoptosis. These effects approached statistical significance in a multivariate model and the cell proliferation index approached statistical significance on univariate analysis.

CONCLUSION

In this pilot study a 4 week regimen of celecoxib resulted in measurable biological effects in prostate cancer tissue. These findings warrant further investigation.

摘要

未标记

环氧化酶-2（COX-2）与肿瘤促进、细胞凋亡抑制、血管生成和转移相关。使用免疫组织化学方法，对临床局限性前列腺癌患者研究了选择性COX-2抑制剂塞来昔布。

患者与方法

cT1-2期前列腺癌患者（n = 45）在根治性前列腺切除术前行随机分组，一组服用塞来昔布400mg，每日两次，另一组不治疗，为期四周。术前活检和配对的根治性前列腺切除术标本的组织学切片进行细胞增殖标志物（MIB-1/Ki-67）、微血管密度（采用魏德纳评分的CD-31）、COX-2、细胞凋亡（TUNEL分析）、血管生成因子（VEGF和KDR）以及HIF-1染色。